- Home
- ABSI vs XFOR Comparison
ABSI vs XFOR Comparison
Compare ABSI & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | XFOR |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.9M | 407.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABSI | XFOR |
|---|---|---|
| Price | $3.10 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $7.47 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 4.3M | 427.6K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,534,000.00 | N/A |
| Revenue This Year | $631.04 | N/A |
| Revenue Next Year | $75.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $0.17 |
| 52 Week High | $5.23 | $6.63 |
Technical Indicators
Market Signals| Indicator | ABSI | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 51.42 |
| Support Level | $2.45 | $3.41 |
| Resistance Level | $3.27 | $4.16 |
| Average True Range (ATR) | 0.21 | 0.30 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 67.83 | 43.21 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.